|
Real-world treatment patterns and survival of BRAF V600-mutated metastatic non-small cell lung cancer patients. |
| |
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech; Janssen; Lilly; Merck; Xcovery |
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst); Xcovery (Inst) |
Other Relationship - Boehringer Ingelheim; Bristol-Myers Squibb |
| |
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; Guardant Health; Merck |
Research Funding - Bayer (Inst); Carevive Systems (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst) |
| |
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Celgene |
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Kyowa Hakko Kirin (Inst); Novartis (Inst) |
| |
|
Employment - RTI Health Solutions |
Consulting or Advisory Role - Novartis |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Novartis; Novartis (I) |
Stock and Other Ownership Interests - Novartis; Novartis (I) |
| |
|
|
Stock and Other Ownership Interests - Novartis |
| |
|
Consulting or Advisory Role - ARIAD; Array BioPharma; AstraZeneca; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Coherus Biosciences; Epic; Hospira; Huron Consulting; HUYA Bioscience International; Quintiles; Takeda; WCCT Global |
Research Funding - Boehringer Ingelheim |
| |
|
Consulting or Advisory Role - Novartis |
Research Funding - AstraZeneca (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Loxo (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst) |
| |
|
|
Stock and Other Ownership Interests - Novartis |
| |
|
Employment - Novartis; Takeda |
Stock and Other Ownership Interests - Amgen; GlaxoSmithKline; Novartis |
Travel, Accommodations, Expenses - Novartis; Takeda |
| |
|
|
Research Funding - ACEA Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Xcovery (Inst) |
| |
|
Stock and Other Ownership Interests - KEW |
Honoraria - Chugai Pharma |
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; KEW; Lilly; Merck; Novartis |
Research Funding - Genentech/Roche (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Toshiba (Inst) |
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute |